Details
Structure visualisation
Entry information
| Complex | |
| AACDB_ID: | 2945 |
| PDBID: | 6UQR |
| Chains: | A_B |
| Organism: | Homo sapiens |
| Method: | XRD |
| Resolution (Å): | 3.65 |
| Reference: | 10.1038/s41467-019-13815-w |
| Antibody | |
| Antibody: | Ligelizumab Fab |
| Antibody mutation: | No |
| INN (Clinical Trial): | |
| Antigen | |
| Antigen: | IgE |
| Antigen mutation: | No |
| Durg Target: | P01854 |
Sequence information
Antibody
Chain: A
Mutation: NULL
| >6UQR_A|Chain A, C|Ligelizumab|Homo sapiens (9606) QVQLVQSGAEVMKPGSSVKVSCKASGYTFSWYWLEWVRQAPGHGLEWMGEIDPGTFTTNYNEKFKARVTFTADTSTSTAYMELSSLRSEDTAVYYCARFSHFSGSNYDYFDYWGQGTLVTVSSGTGGSGGGGSGGGGSGGGASEIVMTQSPATLSVSPGERATLSCRASQSIGTNIHWYQQKPGQAPRLLIYYASESISGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQSWSWPTTFGGGTKVEIKENLYFQGGSGHHHHHHHH |
Antigen
Chain: B
Mutation: NULL
| >6UQR_B|Chain B, D|IgE|Homo sapiens (9606) APMAEGGGQNHHHHHHHHGGENLYFQGGSCADSNPRGVSAYLSRPSPFDLFIRKSPTITCLVVDLAPSKGTVNLTWSRASGKPVNHSTRKEEKQRNGTLTVTSTLPVGTRDWIEGETYQCRVTHPHLPRALMRSTTKTSGPRAAPEVYAFATPEWPGSRDKRTLACLIQNFMPEDISVQWLHNEVQLPDARHSTTQPRKTKGSGFFVFSRLEVTRAEWEQKDEFICRAVHEAASPSQTVQRAVSVNP |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
| A: GLN1 VAL2 GLY26 TYR27 THR28 TRP31 TYR32 TRP33 SER100 HIS101 PHE102 SER103 GLY104 B: VAL336 SER337 THR373 TRP374 SER375 ARG376 ALA377 GLY379 GLY413 GLU414 THR415 GLN417 ARG419 LEU425 PRO426 ARG427 ALA428 LEU429 MET430 ARG431 SER432 THR434 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 5Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 5 Å from any atom.
Interacting residues (Atom distance based)
